• Explore /
  • Poster
  • / CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.

CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.

Abstract Poster

Authors

null

Gang Chen

NCI/NIH, Bethesda, MD

Gang Chen , Fatima Karzai , Ravi Amrit Madan , Lisa M. Cordes , Marijo Bilusic , Helen Owens , Amy Hankin , Monique Williams , Anna Couvillon , James L. Gulley , William L. Dahut , Anish Thomas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02769962

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5096)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5096

Abstract #

TPS5096

Poster Bd #

318a

Abstract Disclosures

Similar Posters

First Author: Arpit Rao

Poster

2023 ASCO Quality Care Symposium

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

First Author: Nicholas Moffett

First Author: Arpit Rao

First Author: Gero Kramer